JP2012102109A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012102109A5 JP2012102109A5 JP2011274098A JP2011274098A JP2012102109A5 JP 2012102109 A5 JP2012102109 A5 JP 2012102109A5 JP 2011274098 A JP2011274098 A JP 2011274098A JP 2011274098 A JP2011274098 A JP 2011274098A JP 2012102109 A5 JP2012102109 A5 JP 2012102109A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- seq
- nos
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54660204P | 2004-02-20 | 2004-02-20 | |
| US60/546,602 | 2004-02-20 | ||
| US58462304P | 2004-07-01 | 2004-07-01 | |
| US60/584,623 | 2004-07-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554221A Division JP2008501308A (ja) | 2004-02-20 | 2005-02-18 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012102109A JP2012102109A (ja) | 2012-05-31 |
| JP2012102109A5 true JP2012102109A5 (OSRAM) | 2013-03-14 |
| JP6045147B2 JP6045147B2 (ja) | 2016-12-14 |
Family
ID=34915579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554221A Pending JP2008501308A (ja) | 2004-02-20 | 2005-02-18 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
| JP2011274098A Expired - Lifetime JP6045147B2 (ja) | 2004-02-20 | 2011-12-15 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554221A Pending JP2008501308A (ja) | 2004-02-20 | 2005-02-18 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7767792B2 (OSRAM) |
| EP (2) | EP1722808B1 (OSRAM) |
| JP (2) | JP2008501308A (OSRAM) |
| KR (2) | KR101280267B1 (OSRAM) |
| AU (2) | AU2005216082B8 (OSRAM) |
| CA (1) | CA2556632C (OSRAM) |
| ES (1) | ES2536974T3 (OSRAM) |
| WO (1) | WO2005081854A2 (OSRAM) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| JP4414142B2 (ja) * | 2001-05-11 | 2010-02-10 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 特異的結合タンパク質およびその使用 |
| DE60237282D1 (de) * | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP2135879A3 (en) * | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| CA2511910A1 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| US20070009972A1 (en) * | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
| MX2008005640A (es) * | 2005-11-02 | 2008-12-09 | Univ Duke | Quimioterapia e inmunoterapia concurrentes. |
| JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| CN101484807A (zh) * | 2006-03-31 | 2009-07-15 | 麻省理工学院 | 表达突变型egf受体的肿瘤的治疗 |
| WO2008033495A2 (en) * | 2006-09-15 | 2008-03-20 | Life Science Pharmaceuticals | Method for detecting and treating skin disorders |
| CN104013956B (zh) * | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| EP2126087A4 (en) | 2007-02-20 | 2010-10-27 | Anaptysbio Inc | METHODS FOR PRODUCING PHARMACOTHEQUES, AND USES THEREOF |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| USRE47534E1 (en) * | 2007-04-23 | 2019-07-23 | Ramot At Tel Aviv University Ltd. | System, method and a computer readable medium for providing an output image |
| KR20100040840A (ko) | 2007-06-06 | 2010-04-21 | 도만티스 리미티드 | 폴리펩티드，항체 가변 도메인 및 길항제 |
| CN108424454B (zh) * | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| WO2009023266A1 (en) * | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| DE112008003232T5 (de) | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
| WO2009149094A2 (en) * | 2008-06-02 | 2009-12-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Cytotoxic t cell defined egfr peptide and an optimized derivative peptide |
| JP2010006705A (ja) * | 2008-06-13 | 2010-01-14 | Atlas Antibodies Ab | Ｈｅｒ２サブセット |
| US20100004306A1 (en) * | 2008-06-18 | 2010-01-07 | Abbott Laboratories | PIGF-1 Assay and kits and components thereof |
| WO2009155381A1 (en) * | 2008-06-18 | 2009-12-23 | Abbott Laboratories | P/gf-1 companion diagnostic methods and products |
| US8741287B2 (en) * | 2008-06-18 | 2014-06-03 | Abbott Laboratories | PlGF-1 assay and kits and components thereof |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| WO2010077643A1 (en) * | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Masking ligands for reversible inhibition of multivalent compounds |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| RU2011138951A (ru) | 2009-02-23 | 2013-03-27 | Сайтомкс Терапьютикс, Инк. | Пропротеины и способы их применения |
| EP2481754B1 (en) * | 2009-09-22 | 2014-06-18 | Shanghai Yijie Biotechnology Co., Ltd | Specific binding proteins and uses thereof |
| CN103539840B (zh) * | 2010-01-20 | 2015-04-01 | 上海市肿瘤研究所 | 表皮生长因子受体模拟表位肽及其应用 |
| CN102127147B (zh) * | 2010-01-20 | 2014-07-02 | 上海市肿瘤研究所 | 表皮生长因子受体模拟表位肽及其应用 |
| AU2011261161A1 (en) | 2010-06-01 | 2013-01-10 | Ludwig Institute For Cancer Research Limited | Antibodies directed to the unprocessed receptor tyrosine kinase c-Met |
| US9464136B2 (en) | 2010-08-20 | 2016-10-11 | Massachusetts Institute Of Technology | Antibody-based constructs directed against tyrosine kinase receptors |
| RU2610336C2 (ru) | 2011-04-21 | 2017-02-09 | Сиэтл Дженетикс, Инк. | Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение |
| KR101930019B1 (ko) * | 2012-03-27 | 2018-12-17 | 주식회사 녹십자 | 표피 성장 인자 수용체 표면 항원상의 에피토프 및 이의 용도 |
| JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Ｅｇｆｒ結合性ペプチド |
| PE20160996A1 (es) | 2013-12-23 | 2016-11-09 | Bayer Pharma AG | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp |
| CN106459199B (zh) | 2014-03-11 | 2021-01-01 | 瑞泽恩制药公司 | 抗-egfrviii抗体及其用途 |
| TW202330606A (zh) | 2014-03-21 | 2023-08-01 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| JP7236216B2 (ja) | 2015-04-23 | 2023-03-09 | ナントミクス，エルエルシー | がんのネオエピトープ |
| PE20180610A1 (es) | 2015-06-22 | 2018-04-09 | Bayer Pharma AG | CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP3362930A4 (en) | 2015-10-12 | 2019-06-19 | Nantomics, LLC | SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS |
| WO2017162663A1 (de) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
| IL310558B1 (en) | 2016-12-21 | 2025-10-01 | Bayer Pharma AG | Antibody-drug conjugates with enzymatically cleavable groups |
| US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
| SG11202108311RA (en) | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| US20220169747A1 (en) * | 2019-03-22 | 2022-06-02 | Olivia Newton-John Cancer Research Institute | Anti-her2 binding molecules |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| CN111647074B (zh) * | 2020-06-01 | 2023-12-19 | 皖南医学院 | 一种her3二聚化界面抗原肽、重组抗原肽、编码基因及其应用 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4359440A1 (en) | 2021-06-22 | 2024-05-01 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibody drug conjugates and uses thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE31006E (en) | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| EP0043718B1 (en) | 1980-07-07 | 1984-11-28 | National Research Development Corporation | Improvements in or relating to cell lines |
| US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
| US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
| US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
| US4451570A (en) | 1981-03-26 | 1984-05-29 | The Regents Of The University Of California | Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
| US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU633867B2 (en) | 1989-02-02 | 1993-02-11 | Eli Lilly And Company | Delivery of cytotoxic agents |
| WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5459061A (en) * | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| AU7774391A (en) | 1990-04-20 | 1991-11-11 | Ludwig Institute For Cancer Research | Aberrant, epidermal growth factor receptor dna, rna and protein forms and method |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU649275B2 (en) | 1990-11-06 | 1994-05-19 | Bristol-Myers Squibb Company | Prodrugs for beta-lactamase and uses thereof |
| DE122009000019I1 (de) * | 1991-04-25 | 2009-07-16 | Chugai Seiyaku K K 5 1 | Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| WO1994001137A1 (en) | 1992-07-06 | 1994-01-20 | Hybritech Incorporated | Method for delivery of cytotoxic agents and components thereof |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
| ATE262586T1 (de) | 1994-11-28 | 2004-04-15 | Univ Jefferson | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5708156A (en) * | 1996-05-31 | 1998-01-13 | Ilekis; John V. | Epidermal growth factor receptor-like gene product and its uses |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| AU778199B2 (en) * | 1999-10-29 | 2004-11-25 | Genentech Inc. | Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use |
| JP2003523207A (ja) * | 2000-01-25 | 2003-08-05 | ジェネンテック・インコーポレーテッド | Ｌｉｖ−１関連タンパク質、それをコードするポリヌクレオチド、及び癌の治療へのその利用 |
| AU9500201A (en) | 2000-08-09 | 2002-02-18 | Imclone Systems Inc | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| JP4414142B2 (ja) * | 2001-05-11 | 2010-02-10 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 特異的結合タンパク質およびその使用 |
| AU2002345673B2 (en) * | 2001-06-13 | 2007-04-26 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| US20040248196A1 (en) * | 2001-08-03 | 2004-12-09 | Adams Timothy Edward | Methods of screening based on the egf receptor crystal structure |
| AU2003236346A1 (en) * | 2002-04-11 | 2003-10-20 | Fuso Pharmaceutical Industries, Ltd. | Monoclonal antibody neutralizing megsin |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| WO2005118876A2 (en) * | 2004-06-04 | 2005-12-15 | Genentech, Inc. | Egfr mutations |
| CN101115849A (zh) * | 2004-12-07 | 2008-01-30 | 健泰科生物技术公司 | 选择her抑制剂疗法的患者 |
| WO2008033495A2 (en) | 2006-09-15 | 2008-03-20 | Life Science Pharmaceuticals | Method for detecting and treating skin disorders |
| CN104013956B (zh) * | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| CA2680854C (en) * | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| CN108424454B (zh) * | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2005
- 2005-02-17 US US11/060,646 patent/US7767792B2/en active Active
- 2005-02-18 ES ES05723258.9T patent/ES2536974T3/es not_active Expired - Lifetime
- 2005-02-18 AU AU2005216082A patent/AU2005216082B8/en not_active Expired
- 2005-02-18 EP EP05723258.9A patent/EP1722808B1/en not_active Expired - Lifetime
- 2005-02-18 KR KR1020067019405A patent/KR101280267B1/ko not_active Expired - Lifetime
- 2005-02-18 CA CA2556632A patent/CA2556632C/en not_active Expired - Lifetime
- 2005-02-18 KR KR1020127010335A patent/KR101270443B1/ko not_active Expired - Lifetime
- 2005-02-18 JP JP2006554221A patent/JP2008501308A/ja active Pending
- 2005-02-18 WO PCT/US2005/005155 patent/WO2005081854A2/en not_active Ceased
- 2005-02-18 EP EP12164335A patent/EP2514763A1/en not_active Withdrawn
-
2010
- 2010-01-29 US US12/657,919 patent/US8652473B2/en not_active Expired - Lifetime
- 2010-09-20 AU AU2010224335A patent/AU2010224335B2/en not_active Expired
-
2011
- 2011-12-15 JP JP2011274098A patent/JP6045147B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012102109A5 (OSRAM) | ||
| Gandullo-Sánchez et al. | HER3 in cancer: from the bench to the bedside | |
| JP7118117B2 (ja) | 抗体－薬物コンジュゲートの選択的製造方法 | |
| Fang et al. | A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice | |
| Reichert | Antibodies to watch in 2010 | |
| Bordeau et al. | Strategies to enhance monoclonal antibody uptake and distribution in solid tumors | |
| JP2020529863A (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP2009526010A5 (OSRAM) | ||
| Parakh et al. | Antibody drug conjugates in glioblastoma–is there a future for them? | |
| JP2006506977A5 (OSRAM) | ||
| JP2015534577A5 (OSRAM) | ||
| Wang et al. | Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy | |
| Flynn et al. | Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (ie, CART) | |
| Tao et al. | Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| Dai et al. | Growth factor signaling and resistance to cancer chemotherapy | |
| Tojjari et al. | Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2 | |
| Lu et al. | Exploring the therapeutic potential of ADC combination for triple-negative breast cancer | |
| Yao et al. | Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase | |
| Nathoo et al. | Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas | |
| JP2020537690A (ja) | プレクチン１結合抗体およびその使用 | |
| Gatto et al. | Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022 | |
| Barginear et al. | Trastuzumab-DM1: a review of the novel immuno-conjugate for HER2-overexpressing breast cancer | |
| Than et al. | A Conjugate of an EGFR-Binding Peptide and Doxorubicin Shows Selective Toxicity to Triple-Negative Breast Cancer Cells | |
| JP7130243B2 (ja) | 二重特異性抗体を用いた抗体薬物複合体プラットホーム |